Key facts
- It has raised $2.5M; the latest was Seed Round ($2.5M) in May 2025.
- Status: Privately Held (backing).
- ·Watchlist + deal alerts for MantaBio
- ·The full record, as it builds
Funding rounds
No funding rounds for MantaBio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About MantaBio
Developer of a real-time polymerase chain reaction (PCR) platform designed for automated microbial contamination detection for biopharma applications. The company's platform provides fully automated, rapid molecular testing at the point-of-need to detect most pathogens, biological contaminants and improve manufacturing efficiency and address the unmet market need for rapid microbial contamination testing, enabling manufacturers to reduce downtime, avoid batch loss and respond quickly when every hour matters.
- Sector
- Healthcare
- HQ
- Beverly, MA, United States
- Founded
- 2025
- Employees
- 8
- Website
- mantabio.com/
- Ownership
- Privately Held (backing)
MantaBio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in MantaBio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on MantaBio in its N-PORT filings yet. We sweep new filings monthly.